$亚盛医药-B(06855)$再探亚盛布局GSPT1分子胶的目的:2021年ASH会议,先行者BMS揭示了CC-90009的联合用药效果。庆幸CC-90009毒性高,期待亚盛的更优效更安全分子胶能够与奥雷巴替尼、力胜克拉联合绽放光彩。 文章题目:Synergistic Combination Activity of the Novel GSPT1 Degrader
are, or have been, employees and equity holders at BMS. J.E.D. served on the Science Advisory Board (SAB) at Trillium Therapeutics, and has ownership interest (including patents) in Trillium Therapeutics Inc.There is an existing license agreement between TTI and University Health Network, and...